Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015
Cadila Healthcare Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2015, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Cadila Healthcare gets EIR report from USFDA
Establishment Inspection Report is given to an establishment after the completion of the inspection by the FDA Zydus' Baddi Plant successfully obtains the Establishment Inspection Report from the USFDA
Cadila Healthcare Ltd has informed BSE that "Our state-of-the-art manufacturing plant at Baddi, Himachal Pradesh, has successfully obtained the Establishment Inspection Report from the USFDA. This will now pave the way for further approval of products from this site". USFDA alleges Cadila's 2 plants for violating CGMP regulations
Torn notebook with record of 'deficiencies', plastic bags filled with shreds of paperwork, failure to adequately investigate and address consumer complaints, are some of the major norm violations found by the USFDA at Cadila Healthcare's two plants in Gujarat. Zydus expands animal health business with a strategic acquisition
Cadila Healthcare Ltd has informed BSE that the Board of Directors of the Company at its meeting held on January 05, 2016, approved the proposal to expand its animal health business with a strategic acquisition.In this regard, the Company has issued a Press Release dated January 05, 2016, titled "Zydus expands animal health business with a strategic acquisition". Cadila Healthcare shares bounce back, up nearly 2%
The stock ended with a gain of 1.27 per cent at Rs 331.95 on BSE. During the day, it climbed 3.11 per cent to Rs 338. Cadila: Warning letters pose fresh challenges
It received the letters from USFDA for compliance-related issues at its Moraiya formulation plant and Zyfine active pharmaceutical ingredients facility in Ahmedabad
Cadila gets FDA warning letter on two plants; stock dips nearly 17%
Cadila receives warning letter from FDA for violating manufacturing standards at its Moraiya formulation facility and Ahmedabad oncology API facility Updates on Warning Letter - US FDA
Cadila Healthcare Ltd has informed BSE that :"The Company has received a Warning Letter issued by the US FDA relating to its Moraiya formulation facility and Ahmedabad API facility (Zyfine).We take quality and compliance matters very seriously and stand by our commitment to fully comply with cGMP quality standards across all our facilities. The Company is working hard to ensure that the commitments made to the US FDA are fully completed.... Will Cadila, Holcim deal get FIPB nod?
The Foreign Investment Promotion Board on Wednesday will take up 16 investment proposals including that of Cadila Healthcare and Holcim (lndia). Cadila Healthcare is seeking approval for fresh equ...